In Taiwan, more than half of patients with lung adenocarcinoma carry an EGFR gene mutation, making EGFR tyrosine kinase inhibitors (TKIs) the mainstay of treatment. Third-generation drugs have pushed disease control beyond a year and a half, but nearly all patients eventually face resistance. The good news: resistance is no longer a full stop — it is the starting point for the next stage of treatment strategy.

First, understand: how does the tumor "escape"?

The first step in managing resistance today is to retest at the time of disease progression — through a tumor biopsy or liquid biopsy (a blood test to examine circulating tumor DNA). Common resistance mechanisms include secondary mutations in EGFR itself (such as C797S), MET gene amplification, HER2 amplification, and transformation to small cell lung cancer. Different mechanisms call for completely different approaches, which is why "re-biopsy" or "re-testing blood" matters so much.

Three major new strategies

First, fourth-generation EGFR-TKIs: a new generation of drugs designed to target secondary mutations such as C797S has shown in early trials that it can re-suppress tumors that have become resistant to third-generation drugs, and a phase 2 trial is now enrolling in Taiwan.

Second, bispecific antibodies and combination therapy: for resistance mechanisms such as MET amplification — a form of "bypass activation" — a bispecific antibody that inhibits both EGFR and MET, combined with a third-generation TKI, has been proven in phase 3 trials to be superior to chemotherapy, becoming one of the standard options after resistance.

Third, ADCs and immunotherapy combinations: an ADC targeting HER3 has shown activity in patients with EGFR mutations after multiple lines of treatment; and the combination of "chemotherapy + immunotherapy + anti-angiogenesis" has also been proven in some phase 3 trials to prolong progression-free survival after resistance.

Advice for patients and families

When facing resistance, the most important thing is not to see "progression" as the end of treatment. Discuss with your doctor the feasibility of repeat genetic testing, what standard treatment options are currently available, and whether you meet the enrollment criteria for a clinical trial. Treatment options after resistance are increasing at an unprecedented pace, and joining a well-designed clinical trial is often the best way to access the newest drugs.